ALK-Abelló A/S
ALK-B
Classement en actions
#2354
ALK-Abelló A/S is a global leader in allergy solutions, with operations... ALK-Abelló A/S is a global leader in allergy solutions, with operations spanning Europe, North America, and other international regions. The company offers a comprehensive portfolio of treatments for allergic rhinitis and allergic asthma, featuring key products such as GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX. ALK-Abelló specializes in allergy immunotherapy, providing options like injections, sublingual drops, and tablets to address a wide range of sensitivities, including those to grass, ragweed, house dust mites, Japanese cedar, various tree pollens, and certain foods. Furthermore, the company engages with consumers through a digital healthcare ecosystem, a platform designed to connect with allergy sufferers early in their journey, offering tools, e-commerce solutions, and guidance to support and streamline access to immunotherapy. ALK-Abelló also provides essential diagnostic allergy services, including skin prick and blood tests, alongside emergency treatments such as intramuscular adrenaline injections for severe, life-threatening allergic reactions like anaphylaxis. The company was established in 1923 and is based in Hørsholm, Denmark.
Prix de l'action
$37.76
Dernière synchronisation: 2026-10-20
Capitalisation boursière
$8.38B
Changement (1 jour)
-0.08%
Changement (1 an)
14.34%
Pays
DK
Échange ALK-Abelló A/S (ALK-B)
Catégorie
Healthcare
Bénéfices pour ALK-Abelló A/S (ALK-B)
Bénéfices en Jun 2026 TTM : $293.25M
Selon les derniers rapports financiers de ALK-Abelló A/S, les bénéfices actuels de l'entreprise sont de $293.25M. En 2023, l'entreprise a réalisé un bénéfice de $95.80M, une augmentation par rapport à celui de 2022 qui était de $64.34M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour ALK-Abelló A/S de 2004 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $293.25M | 98.85% |
| 2024 | $147.48M | 53.95% |
| 2023 | $95.80M | 48.90% |
| 2022 | $64.34M | 50.79% |
| 2021 | $42.67M | 157.35% |
| 2020 | $16.58M | -456.36% |
| 2019 | $-4.65M | -70.59% |
| 2018 | $-15.82M | -19.54% |
| 2017 | $-19.66M | -128.45% |
| 2016 | $69.12M | 18.58% |
| 2015 | $58.29M | 19.46% |
| 2014 | $48.79M | 154.41% |
| 2013 | $19.18M | -4.03% |
| 2012 | $19.98M | -64.26% |
| 2011 | $55.91M | 50.59% |
| 2010 | $37.12M | 1.19% |
| 2009 | $36.69M | 25.00% |
| 2008 | $29.35M | -35.66% |
| 2007 | $45.62M | 177.96% |
| 2006 | $16.41M | -257.10% |
| 2005 | $-10.45M | -128.29% |
| 2004 | $36.93M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| $5.27B | 1,698.75% |
US
|
|
| $-3.09B | -1,152.67% |
US
|
|
| $-4.02B | -1,469.53% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 565.18% |
NL
|
